Abstract: Oxaliplatin (OXP) is a third-generation platinum-based chemotherapeutic agent that serves as a cornerstone in the treatment of colorectal cancer (CRC). Despite its clinical success, the development of intrinsic and acquired chemoresistance significantly limits its long-term efficacy and patient survival rates. This literature review synthesizes current research on the molecular mechanisms underlying oxaliplatin resistance, which include altered drug transport, enhanced detoxification via glutathione, upregulated DNA repair pathways, epigenetic modifications, and the influence of the tumor microenvironment (TME). Furthermore, this review explores emerging reversal strategies and structure-activity relationship (SAR) insights, highlighting the development of Pt(IV) prodrugs, epigenetic modulators, and advanced nanodelivery systems. Finally, we discuss current clinical limitations, particularly oxaliplatin-induced peripheral neuropathy (OIPN), and outline future perspectives in personalized medicine and chemoimmunotherapy to overcome resistance.
1. Introduction
Since the discovery of cisplatin's anticancer properties, platinum-based drugs have become a fundamental component of cancer therapy. Oxaliplatin is a third-generation platinum compound developed to overcome the severe toxicities and resistance profiles associated with earlier generations like cisplatin and carboplatin [3]. It is primarily utilized as a first-line and adjuvant treatment for colorectal cancer (CRC), most notably in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in the FOLFOX regimen [1]. While the addition of oxaliplatin to CRC treatment regimens has significantly improved objective response rates and overall survival, the emergence of chemoresistance remains a formidable clinical challenge. Resistance to oxaliplatin is a multifactorial process that can be intrinsic—driven by tumor heterogeneity and genetic mutations—or acquired following prolonged exposure to the drug [1]. Understanding these resistance mechanisms is critical for developing novel therapeutic strategies and next-generation platinum agents capable of restoring chemosensitivity.
2. Pharmacological Activity
The primary pharmacological activity of oxaliplatin involves its interaction with DNA. Upon entering the cell, oxaliplatin forms bulky and highly hydrophobic platinum-DNA adducts. These adducts physically distort the DNA helix, inhibiting DNA synthesis and cellular proliferation, ultimately triggering severe cellular stress and apoptosis [1] [2]. In addition to its direct cytotoxic effects, oxaliplatin is recognized for its immunomodulatory properties. It is capable of inducing immunogenic cell death (ICD), a process that stimulates the immune system to recognize and attack tumor cells [1] [4]. Oxaliplatin treatment has been shown to reverse the immunosuppressive tumor microenvironment by enriching the infiltration of CD8+ T cells, natural killer (NK) cells, and dendritic cells, while simultaneously depleting immunosuppressive cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) [1].
3. Molecular Mechanism of Action of Resistance
Resistance to oxaliplatin is highly complex and involves multiple cellular and extracellular adaptations:
Altered Drug Transport: The cellular accumulation of oxaliplatin is tightly regulated by influx and efflux transporters. Decreased expression of organic cation transporters (OCT1-3) and the copper transporter CTR1 reduces the cellular uptake of the drug [1] [2]. Conversely, the overexpression of efflux pumps, such as ATP-binding cassette (ABC) transporters (e.g., MRP2/ABCC2) and copper transporters (ATP7A and ATP7B), actively pumps the drug out of the cell, thereby diminishing its intracellular concentration and efficacy [1] [2].
Detoxification and Sequestration: Cancer cells actively sequester oxaliplatin by generating nucleophilic scavengers, most notably glutathione (GSH). Elevated levels of GSH and glutathione S-transferases (GSTs) catalyze the conjugation of oxaliplatin to GSH, inactivating the drug and facilitating its export via MRP2 [1] [2].
Enhanced DNA Repair: The nucleotide excision repair (NER) pathway is crucial for recognizing and excising platinum-DNA adducts. Upregulation of NER proteins, particularly excision repair cross-complementation group 1 (ERCC1), is a hallmark of oxaliplatin-resistant tumors and correlates with poor clinical response to FOLFOX therapy [1] [2].
Tumor Microenvironment (TME) and Epigenetics: The TME, including cancer-associated fibroblasts (CAFs), secretes soluble factors like IL-6 and TGF-β that activate survival pathways (e.g., PI3K/AKT and JAK/STAT) and inhibit apoptosis [1]. Furthermore, epigenetic modifications, such as the DNA hypermethylation of the BRCA1 interactor SRBC gene, and the epigenetic regulation of epithelial-mesenchymal transition (EMT) markers, promote the development of drug-tolerant persister cells and cancer stem cells (CSCs) [1].
Survival Pathways: The constitutive activation of signaling pathways, such as the NF-κB and MAPK pathways, leads to the upregulation of anti-apoptotic genes, allowing cancer cells to evade oxaliplatin-induced cell death [1] [2].
4. Structure-Activity Relationship (SAR) and Reversal Strategies
The unique structure of oxaliplatin, which features a trans-(1R,2R)-diaminocyclohexane (DACH) carrier ligand and a bidentate oxalate leaving group, is central to its lack of cross-resistance with cisplatin and carboplatin [1] [3]. The DACH ligand leads to the formation of distinct, bulkier DNA adducts that are less efficiently recognized by cellular DNA repair proteins [1].
To overcome resistance, researchers are exploiting SAR principles to design Pt(IV) prodrugs. These octahedral complexes are synthesized by adding axial ligands to the square-planar Pt(II) core. This modification increases lipophilicity, enhances cellular uptake, and prevents premature deactivation. More importantly, the axial positions can be conjugated with bioactive molecules to create dual-action prodrugs. Examples include conjugating oxaliplatin with nonsteroidal anti-inflammatory drugs (NSAIDs), histone deacetylase (HDAC) inhibitors, GST inhibitors, or NF-κB inhibitors to simultaneously induce DNA damage and dismantle resistance pathways [1].
Other pharmacological reversal strategies include the use of epigenetic modulators. DNA methyltransferase inhibitors (e.g., decitabine) and HDAC inhibitors (e.g., SAHA/Vorinostat) have shown success in reverting oxaliplatin resistance by reducing HDAC2 levels and inducing mitotic cell death [1]. Additionally, natural compounds like curcumin can reverse resistance by modulating the CXC-chemokine/NF-κB signaling pathway [1]. To combat GSH-mediated detoxification, GSH-scavenging agents (e.g., sulforaphane) have been co-delivered with platinum drugs using nanocarriers to deplete intracellular GSH and restore sensitivity [3].
5. Current Limitations
Despite its efficacy, the clinical utility of oxaliplatin is hindered by severe, dose-limiting toxicities. The most prominent is oxaliplatin-induced peripheral neuropathy (OIPN), which manifests as acute cold-triggered dysesthesia and chronic sensory neuropathy. OIPN is largely attributed to the oxalate leaving group, which acts as a calcium chelator, disrupting calcium homeostasis and altering the function of voltage-gated sodium channels in dorsal root ganglion (DRG) neurons [1]. Currently, there are no FDA-approved pharmacological treatments to prevent OIPN, often necessitating dose reduction or cessation of therapy [1].
Furthermore, traditional oxaliplatin lacks tumor specificity, leading to systemic side effects. The dense extracellular matrix and abnormal vasculature of the CRC TME act as physical barriers, impeding adequate drug delivery to the tumor core. Additionally, the hypoxic and immunosuppressive nature of the TME counteracts the drug's efficacy and promotes the survival of resistant cell populations [1].
6. Future Perspectives
The future of oxaliplatin-based therapy lies in precision medicine and advanced drug delivery systems. The identification of reliable predictive biomarkers is a major research focus. Non-coding RNAs, including microRNAs (e.g., miR-128-3p, miR-34a), long non-coding RNAs (e.g., lncRNA TUG1, CCAL), and circular RNAs (e.g., circHIPK3), have emerged as promising non-invasive biomarkers for predicting FOLFOX sensitivity and serving as potential therapeutic targets [1]. Additionally, classifying tumors by Consensus Molecular Subtypes (CMS), particularly identifying the mesenchymal CMS4 subtype, can help predict poor responses to oxaliplatin [1].
To improve specificity and overcome efflux-mediated resistance, nanotechnology-based delivery systems are being heavily investigated. Encapsulating oxaliplatin in liposomes, polymeric micelles, or gold nanoshells can exploit the enhanced permeability and retention (EPR) effect. Surface functionalization with targeting ligands (e.g., hyaluronic acid, transferrin, or EGFR antibodies like cetuximab) facilitates receptor-mediated endocytosis, bypassing traditional membrane transporters [1] [3].
Finally, the integration of oxaliplatin with immunotherapy (e.g., immune checkpoint inhibitors) and the development of photo- or radio-activatable Pt(IV) prodrugs represent cutting-edge approaches. These strategies aim to localize drug activation strictly within the tumor site and leverage oxaliplatin's ability to induce immunogenic cell death, thereby transforming "cold" resistant tumors into immunologically "hot" tumors for durable clinical responses [1].
